Although the third-generation EGFR-TKIs can conquer resistance caused by the T790M mutation and are now the first-line standard for treating EGFR-mutant NSCLC (non-small cell lung cancer), acquired resistance remains a challenge [4]. Here, EGFR is linked to non-small cell lung carcinoma.